Bioequivalent Drugs: Towards A Needed Holistic
Paradigm Shift?
Volume 2 - Issue 4
François-Xavier Lacasse*
-
Author Information
Open or Close
- Faculty of Pharmacy, University of Montreal, Canada
*Corresponding author:
François-Xavier Lacasse, Faculty of Pharmacy, University of Montreal, Canada
Received:October 17, 2018; Published: October 24, 2018
DOI: 10.32474/DDIPIJ.2018.02.000144
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
The author of this short communication has been working in
and teaching drug development for the last 20 years. He has been
involved in more than 100 drug development projects, including
drug delivery, medical device, biologics, innovators and generic
drugs. He has also been involved in all the steps that are needed
to file properly to different governmental agencies investigational
new drug applications (IND), clinical trial applications (CTA),
abbreviated and new drug applications/submissions (ANDA\S;
NDA/S), 505b2, 510k and biologics legal applications (BLA). After
several other interactions with all the other actors, such as Health
Canada (HC), the Food and Drug Agency (FDA), the European
Medicines Agency (EMA), pharmacovigilance companies and
consultants, public relation companies, insurance companies
and especially patients, the author has decided to gather all
the comments in order to initiate a kind of a new debate on the
innovators and generic drugs. However, the goal of this current
expert opinion is not to generate conflicts, or to compare generic
versus innovator drugs in the sense that one is better than the other.
The author has already been involved in several bioequivalence
studies, comparing two innovator products where the results
showed lack of bioequivalence….or in bioequivalence studies
evaluated with clinical endpoint where generic drug products were
more potent than the innovators…The goal of this paper should be
more based on the following question: are the current methods
used to assess bioequivalence are suitable and reliable enough to
“stamp” that generic drugs are bioequivalent, are as stable, reliable
form a quality, a safety and efficacy standpoints.
Opinion|
Bioequivalence…. What Does It Mean?|
So…Finally Can Generic Drugs Be Considered on
the Same Footing Than Innovators?|
Refernces|